278 related articles for article (PubMed ID: 27497504)
1. Statin Intolerance: A Literature Review and Management Strategies.
Saxon DR; Eckel RH
Prog Cardiovasc Dis; 2016; 59(2):153-164. PubMed ID: 27497504
[TBL] [Abstract][Full Text] [Related]
2. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
Schreml J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
[TBL] [Abstract][Full Text] [Related]
3. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
6. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
7. Resistance and intolerance to statins.
Reiner Z
Nutr Metab Cardiovasc Dis; 2014 Oct; 24(10):1057-66. PubMed ID: 24996502
[TBL] [Abstract][Full Text] [Related]
8. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle.
Glueck CJ; Abuchaibe C; Wang P
Med Hypotheses; 2011 Oct; 77(4):658-61. PubMed ID: 21802861
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
[TBL] [Abstract][Full Text] [Related]
11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
12. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
13. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
Robinson JG
Prog Cardiovasc Dis; 2016; 59(2):165-171. PubMed ID: 27498088
[TBL] [Abstract][Full Text] [Related]
14. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?
Brennan ET; Joy TR
Can J Cardiol; 2017 May; 33(5):666-673. PubMed ID: 28449837
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Statin Intolerance.
Alonso R; Cuevas A; Cafferata A
J Atheroscler Thromb; 2019 Mar; 26(3):207-215. PubMed ID: 30662020
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidemia: management using optimal lipid-lowering therapy.
Ito MK
Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
[TBL] [Abstract][Full Text] [Related]
17. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
18. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
19. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
Degreef LE; Opdam FL; Teepe-Twiss IM; Jukema JW; Guchelaar HJ; Tamsma JT
Eur J Intern Med; 2010 Aug; 21(4):293-6. PubMed ID: 20603038
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy in dyslipidemia: where are we now?
Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
